SION — Sionna Therapeutics, Inc. stock price, charts and financials

QT87Sionna Therapeutics, Inc.

Sionna Therapeutics, Inc. (NASDAQ: SION) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
49.26
+2.13+4.52%
OverviewShort InterestFilings
SIONQT87Sionna Therapeutics, Inc.·NASDAQ
49.26+4.52%
TA
Loading chart...
Screen all →
IMNM+1.10%$23.01KLRA+2.24%$17.32NUVB-2.69%$6.16ZLAB-0.49%$18.18HRMY+1.02%$35.60BHVN-0.96%$13.37PGEN+5.42%$6.61MLYS+1.02%$25.78
Snapshot
Index-P/E-EPS (ttm)-Insider Own-Shs Outstand45.15MPerf Week3.13%
Market Cap2.13BForward P/E-EPS next Y-2.83Insider Trans-8.79%Shs Float26.61MPerf Month13.18%
Enterprise Value2.07BPEG0.96EPS next Q-Inst Own-Short Float19.76%Perf Quarter21.78%
Income-85.97MP/S0.00EPS this Y-Inst Trans-Short Ratio12.01Perf Half Y11.05%
Sales0.00P/B7.35EPS next Y-9.07%ROA-28.05%Short Interest5.26MPerf YTD14.56%
Book/sh-P/C-EPS next 5Y-ROE-27.31%52W High53.90 -8.61%Perf Year165.52%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-33.35%52W Low17.12 187.73%Perf 3Y-
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility5.91% 7.56%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-37.86%Oper. Margin0.00%ATR (14)3.24Perf 10Y-
Dividend Ex-Date-Quick Ratio22.60Sales Y/Y TTM-Profit Margin0.00%RSI (14)57.40Recom2.43
Dividend Gr. 3/5Y-Current Ratio22.60EPS Q/Q3.23%SMA204.01%Beta0.89Target Price52.50
Payout0.00%Debt/Eq0.03Sales Q/Q-SMA5013.13%Rel Volume0.84Prev Close47.13
Employees59LT Debt/Eq0.02EarningsAug 10SMA20018.34%Avg Volume464.56KPrice49.26
IPO DateFeb 07, 2025Option/ShortYes / YesEPS/Sales Surpr.-16.73% -Net Debt/EBITDA0.68Volume390,624Change4.52%
Analyst Ratings
DateActionAnalystRatingTarget
May-20-26DowngradeFreedom BrokerBuy → Hold
May-18-26ReiteratedStifel Nicolaus$44 → $55
Jan-07-26ReiteratedBTIGBuy$58
Jan-05-26ReiteratedRaymond James$45 → $53
Dec-01-25DowngradeRBC CapitalSector Perform → Underperform$22 → $24
Sep-03-25InitiatedRBC CapitalSector Perform$22
Sep-02-25InitiatedRaymond JamesStrong Buy$45
Mar-04-25InitiatedGuggenheimBuy$45
Latest News
Company

Operating as a biopharmaceutical company, Sionna Therapeutics, Inc. is dedicated to transforming the treatment landscape for individuals with cystic fibrosis. This is achieved by developing innovative medicines designed to restore the normal function of the cystic fibrosis transmembrane conductance regulator.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
Total Revenue
0000
Cost of Goods Sold Incl. D&A1100
Gross Profit-1-100
Selling, General and Administrative Excl. Other2913107
Research and Development60574135
Other Operating Expense-10-1-1
Operating Income-89-71-50-41
Interest Expense
0000
Unusual Expense
————
Non-Operating Income (Expense)14931
Net Income Before Taxes-75-62-47-40
Income Taxes
0000
Consolidated Net Income-75-62-47-40
Net Income From Continuing Operations-75-62-47-40
Net Income-75-62-47-40
EPS (Recurring)-1.88-1.40-1.07-0.91
EPS (Basic, Before Extraordinaries)-1.88-1.40-1.07-0.91
EPS (Diluted)-1.88-1.40-1.07-0.91
EBITDA-75-61-47-40
Other After Tax Adjustments
————
Stock Option Compensation Expense
————
Price To Earnings Ratio
————
Price To Sales Ratio
————
Gross Margin
————
Operating Margin
————
Net Margin
————
Shares Outstanding40444444
Market Capitalization1,646———
Operating Lease Expense
————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$54.91$42.99$31.07$19.14$7.22● Close Price0.00M12.71M25.42M38.13M50.83MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Thompson Peter A.DirectorJul 07 '26Sale44.8685,9183,854,2812,469,959Jul 09
ORBIMED ADVISORS LLCDirectorJul 07 '26Sale44.8685,9183,854,2812,469,959Jul 09
Fitzpatrick JenniferChief Legal OfficerJul 06 '26Option Exercise6.1110,25062,62810,250Jul 07
Fitzpatrick JenniferChief Legal OfficerJul 06 '26Sale43.6010,250446,8620Jul 07
Thompson Peter A.DirectorJun 30 '26Sale45.50115,8445,270,9022,555,877Jul 02
ORBIMED ADVISORS LLCDirectorJun 30 '26Sale45.50115,8445,270,9022,555,877Jul 02
ORBIMED ADVISORS LLCDirectorMay 27 '26Sale44.491014,4932,671,721May 29
Thompson Peter A.DirectorMay 27 '26Sale44.491014,4932,671,721May 29
ORBIMED ADVISORS LLCDirectorMay 11 '26Sale46.22184,6398,534,0152,671,822May 11
Thompson Peter A.DirectorMay 11 '26Sale46.22184,6398,534,0152,671,822May 11
ORBIMED ADVISORS LLCDirectorMay 08 '26Sale44.5859,7672,664,4132,856,461May 11
Thompson Peter A.DirectorMay 08 '26Sale44.5859,7672,664,4132,856,461May 11
ORBIMED ADVISORS LLCDirectorMay 07 '26Sale44.6148,5462,165,6372,916,228May 11
Thompson Peter A.DirectorMay 07 '26Sale44.6148,5462,165,6372,916,228May 11
ORBIMED ADVISORS LLCDirectorApr 18 '26Sale44.522,948131,2452,964,774Apr 21
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.